HRP20211035T1 - Tekuća formulacija za inhalaciju koja sadrži rpl554 - Google Patents
Tekuća formulacija za inhalaciju koja sadrži rpl554 Download PDFInfo
- Publication number
- HRP20211035T1 HRP20211035T1 HRP20211035TT HRP20211035T HRP20211035T1 HR P20211035 T1 HRP20211035 T1 HR P20211035T1 HR P20211035T T HRP20211035T T HR P20211035TT HR P20211035 T HRP20211035 T HR P20211035T HR P20211035 T1 HRP20211035 T1 HR P20211035T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- composition according
- rpl554
- asthma
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims 16
- 239000000203 mixture Substances 0.000 title claims 6
- CSOBIBXVIYAXFM-UHFFFAOYSA-N rpl-554 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2CCNC(N)=O)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C CSOBIBXVIYAXFM-UHFFFAOYSA-N 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002245 particle Substances 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 4
- CSOBIBXVIYAXFM-BYNJWEBRSA-N ensifentrine Chemical compound c-12cc(OC)c(OC)cc2CCn(c(n2CCNC(N)=O)=O)c-1c\c2=N/c1c(C)cc(C)cc1C CSOBIBXVIYAXFM-BYNJWEBRSA-N 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- -1 polyoxyethylene Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Tekući farmaceutski sastav pogodan za davanje inhalacijom koji sadrži razrjeđivač i suspenziju čestica 9,10-dimetoksi-2-(2,4,6-trimetilfenilimino)-3-(N-karbamoil-2-aminoetil)-3,4,6,7-tetrahidro-2Hpirimido[6,1-a]izohinolin-4-ona (RPL554) ili njegove farmaceutski prihvatljive soli, pri čemu:
čestice RPL554 imaju raspodjelu veličine čestica sa Dv50 (srednja vrijednost veličine čestice po obujmu) vrijednosti od 0.2 µm do 5 µm; i
sastav sadrži fosfatni pufer u koncentraciji od 0 mg/mL do 5 mg/mL.
2. Tekući farmaceutski sastav prema zahtjevu 1, pri čemu sastav ne sadrži fosfatni pufer.
3. Tekući farmaceutski sastav prema zahtjevu 1 ili zahtjevu 2, pri čemu sastav ne sadrži pufer.
4. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, pri čemu čestice RPL554 imaju raspodjelu veličine čestice sa Dv50 vrijednosti od 0.7 µm do 2.5 µm.
5. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, pri čemu je koncentracija čestica RPL554 u tekućem farmaceutskom sastavu od 0.01 mg/mL do 40 mg/mL.
6. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva koji dalje sadrži jedan ili više površinski aktivnih sredstava.
7. Tekući farmaceutski sastav prema zahtjevu 6, pri čemu jedno ili više površinski aktivnih sredstava su izabrani između jednog ili više ne-ionskih površinski aktivnih sredstava.
8. Tekući farmaceutski sastav prema zahtjevu 6 ili zahtjevu 7, pri čemu jedno ili više površinski aktivnih sredstava su izabrani između alkil estera polioksietilen glikol sorbitana i alkil estera sorbitana.
9. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, pri čemu sastav dalje sadrži sredstvo za podešavanje toničnosti, po potrebi gdje sredstvo za podešavanje toničnosti je natrij klorid.
10. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, pri čemu je razrjeđivač voda.
11. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva koji je pogodan za davanje sa nebulizatorom.
12. Nebulizator koji sadrži sastav prema bilo kojem od prethodnih zahtjeva.
13. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva 1 do 11 za upotrebu u liječenju ljudskog ili životinjskog tijela.
14. Tekući farmaceutski sastav prema bilo kojem od prethodnih zahtjeva 1 do 11 za upotrebu u liječenju ili prevenciji bolesti ili stanja izabranih između astme, alergijske astme, polenske groznice, alergijskog rinitisa, bronhitisa, emfizema, bronhiektazije, kronične opstruktivne bolesti pluća (COPD), respiratornog distres sindroma kod odraslih (ARDS), astme koja je otporna na steroide, teškog oblika astme, pedijatrijske astme, cistične fibroze, fibroze pluća, plućne fibroze, intersticijalne bolesti pluća, poremećaja kože, atopijskog dermatitisa, psorijaze, upale oka, cerebralne ishemije, upalnih bolesti i auto-imunih bolesti.
15. Tekući farmaceutski sastav za upotrebu prema zahtjevu 14 pri čemu je bolest ili stanje kronična opstruktivna bolest pluća (COPD).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1416274.7A GB201416274D0 (en) | 2014-09-15 | 2014-09-15 | Formulation |
| GBGB1504662.6A GB201504662D0 (en) | 2015-03-19 | 2015-03-19 | Formulation |
| EP19152629.2A EP3494962B1 (en) | 2014-09-15 | 2015-09-15 | Liquid inhalation formulation comprising rpl554 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211035T1 true HRP20211035T1 (hr) | 2021-09-17 |
Family
ID=54196992
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180833TT HRP20180833T1 (hr) | 2014-09-15 | 2018-05-25 | Tekući pripravak za inhalaciju koji sadrži rpl554 |
| HRP20191122TT HRP20191122T1 (hr) | 2014-09-15 | 2019-06-19 | Tekući inhalacijski pripravak koji sadrži rpl554 |
| HRP20211035TT HRP20211035T1 (hr) | 2014-09-15 | 2021-06-30 | Tekuća formulacija za inhalaciju koja sadrži rpl554 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180833TT HRP20180833T1 (hr) | 2014-09-15 | 2018-05-25 | Tekući pripravak za inhalaciju koji sadrži rpl554 |
| HRP20191122TT HRP20191122T1 (hr) | 2014-09-15 | 2019-06-19 | Tekući inhalacijski pripravak koji sadrži rpl554 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9956171B2 (hr) |
| EP (3) | EP3332767B1 (hr) |
| JP (2) | JP6860477B2 (hr) |
| KR (1) | KR102379309B1 (hr) |
| CN (3) | CN106794157B (hr) |
| AU (3) | AU2015316592B2 (hr) |
| CA (1) | CA2959943C (hr) |
| CY (3) | CY1120264T1 (hr) |
| DK (3) | DK3494962T3 (hr) |
| ES (3) | ES2670025T3 (hr) |
| HK (1) | HK1249415B (hr) |
| HR (3) | HRP20180833T1 (hr) |
| HU (3) | HUE055527T2 (hr) |
| IL (1) | IL250895B (hr) |
| LT (3) | LT3193835T (hr) |
| MX (1) | MX2017003102A (hr) |
| MY (1) | MY196072A (hr) |
| NO (1) | NO3193835T3 (hr) |
| NZ (3) | NZ767296A (hr) |
| PH (1) | PH12017500479B1 (hr) |
| PL (3) | PL3193835T3 (hr) |
| PT (3) | PT3193835T (hr) |
| RS (3) | RS57227B1 (hr) |
| RU (1) | RU2699995C2 (hr) |
| SG (1) | SG11201701854WA (hr) |
| SI (3) | SI3193835T1 (hr) |
| WO (1) | WO2016042313A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2682105T3 (es) | 2014-05-12 | 2018-09-18 | Verona Pharma Plc | Nuevo tratamiento |
| NZ767296A (en) * | 2014-09-15 | 2024-01-26 | Verona Pharma Plc | Liquid inhalation formulation comprising rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| WO2017016982A1 (en) | 2015-07-24 | 2017-02-02 | F. Hoffmann-La Roche Ag | Bace1 inhibitor peptides |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| GB201911517D0 (en) | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| EP4092025A4 (en) * | 2020-01-15 | 2023-08-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | PHARMACEUTICAL COMPOSITION OF A TRICYCLIC PDE3/PDE4 DOUBLE INHIBITOR COMPOUND |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024033627A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
| WO2024033624A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Plc | Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd) |
| WO2024088364A1 (zh) * | 2022-10-28 | 2024-05-02 | 江苏恒瑞医药股份有限公司 | 一种包含异喹啉酮类化合物的药物组合物及其制备方法 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
| JP3676674B2 (ja) * | 1997-10-09 | 2005-07-27 | シェーリング コーポレイション | 噴霧のためのモメタゾンフロエート懸濁液 |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| US6630169B1 (en) * | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
| EP1165558B1 (en) | 1999-03-31 | 2003-09-24 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0122031D0 (en) * | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
| US7579505B2 (en) | 2004-12-17 | 2009-08-25 | Cipla Limited | Crystalline levosalbutamol sulphate and polymorphic forms thereof |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| KR20130087405A (ko) * | 2010-06-22 | 2013-08-06 | 키에시 파르마슈티시 엣스. 피. 에이. | 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물 |
| KR101860968B1 (ko) | 2010-08-09 | 2018-05-24 | 베로나 파마 피엘씨 | 피리미도[6,1-ａ]이소퀴놀린-4-원 화합물의 결정 형태 |
| US8945605B2 (en) * | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| AU2012267938B2 (en) * | 2011-06-07 | 2017-05-04 | Parion Sciences, Inc. | Methods of treatment |
| EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| WO2014037727A1 (en) | 2012-09-06 | 2014-03-13 | Verona Pharma Plc | Carcainium salts |
| PT2968312T (pt) * | 2013-03-15 | 2018-04-19 | Verona Pharma Plc | Combinação de fármacos |
| ES2682105T3 (es) | 2014-05-12 | 2018-09-18 | Verona Pharma Plc | Nuevo tratamiento |
| NZ767296A (en) * | 2014-09-15 | 2024-01-26 | Verona Pharma Plc | Liquid inhalation formulation comprising rpl554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2015
- 2015-09-15 NZ NZ767296A patent/NZ767296A/en unknown
- 2015-09-15 HU HUE19152629A patent/HUE055527T2/hu unknown
- 2015-09-15 ES ES15770593.0T patent/ES2670025T3/es active Active
- 2015-09-15 JP JP2017514346A patent/JP6860477B2/ja active Active
- 2015-09-15 NO NO15770593A patent/NO3193835T3/no unknown
- 2015-09-15 NZ NZ729796A patent/NZ729796A/en unknown
- 2015-09-15 PL PL15770593T patent/PL3193835T3/pl unknown
- 2015-09-15 WO PCT/GB2015/052668 patent/WO2016042313A1/en active Application Filing
- 2015-09-15 HU HUE15770593A patent/HUE038433T2/hu unknown
- 2015-09-15 DK DK19152629.2T patent/DK3494962T3/da active
- 2015-09-15 PT PT157705930T patent/PT3193835T/pt unknown
- 2015-09-15 EP EP17207623.4A patent/EP3332767B1/en active Active
- 2015-09-15 RS RS20180519A patent/RS57227B1/sr unknown
- 2015-09-15 EP EP15770593.0A patent/EP3193835B1/en active Active
- 2015-09-15 KR KR1020177006862A patent/KR102379309B1/ko active IP Right Grant
- 2015-09-15 PT PT17207623T patent/PT3332767T/pt unknown
- 2015-09-15 HU HUE17207623A patent/HUE045303T2/hu unknown
- 2015-09-15 PL PL19152629T patent/PL3494962T3/pl unknown
- 2015-09-15 LT LTEP15770593.0T patent/LT3193835T/lt unknown
- 2015-09-15 PT PT191526292T patent/PT3494962T/pt unknown
- 2015-09-15 AU AU2015316592A patent/AU2015316592B2/en active Active
- 2015-09-15 PL PL17207623T patent/PL3332767T3/pl unknown
- 2015-09-15 NZ NZ767295A patent/NZ767295A/en unknown
- 2015-09-15 RU RU2017108432A patent/RU2699995C2/ru active
- 2015-09-15 MX MX2017003102A patent/MX2017003102A/es active IP Right Grant
- 2015-09-15 ES ES17207623T patent/ES2730810T3/es active Active
- 2015-09-15 DK DK15770593.0T patent/DK3193835T3/en active
- 2015-09-15 SG SG11201701854WA patent/SG11201701854WA/en unknown
- 2015-09-15 SI SI201530213T patent/SI3193835T1/en unknown
- 2015-09-15 CA CA2959943A patent/CA2959943C/en active Active
- 2015-09-15 ES ES19152629T patent/ES2875584T3/es active Active
- 2015-09-15 EP EP19152629.2A patent/EP3494962B1/en active Active
- 2015-09-15 SI SI201531657T patent/SI3494962T1/sl unknown
- 2015-09-15 US US15/509,943 patent/US9956171B2/en active Active
- 2015-09-15 LT LTEP17207623.4T patent/LT3332767T/lt unknown
- 2015-09-15 CN CN201580053062.1A patent/CN106794157B/zh active Active
- 2015-09-15 CN CN202010090019.5A patent/CN111249260B/zh active Active
- 2015-09-15 MY MYPI2017000391A patent/MY196072A/en unknown
- 2015-09-15 RS RS20211044A patent/RS62252B1/sr unknown
- 2015-09-15 DK DK17207623.4T patent/DK3332767T3/da active
- 2015-09-15 CN CN201811561721.4A patent/CN110051627A/zh active Pending
- 2015-09-15 RS RS20190765A patent/RS58897B1/sr unknown
- 2015-09-15 LT LTEP19152629.2T patent/LT3494962T/lt unknown
- 2015-09-15 SI SI201530774T patent/SI3332767T1/sl unknown
-
2017
- 2017-03-02 IL IL250895A patent/IL250895B/en active IP Right Grant
- 2017-03-14 PH PH12017500479A patent/PH12017500479B1/en unknown
-
2018
- 2018-03-21 US US15/927,517 patent/US10945950B2/en active Active
- 2018-05-03 CY CY20181100455T patent/CY1120264T1/el unknown
- 2018-05-25 HR HRP20180833TT patent/HRP20180833T1/hr unknown
- 2018-07-10 HK HK18108909.3A patent/HK1249415B/zh unknown
- 2018-12-20 JP JP2018238014A patent/JP6795574B2/ja active Active
- 2018-12-24 AU AU2018286571A patent/AU2018286571B2/en active Active
-
2019
- 2019-06-18 CY CY20191100622T patent/CY1121698T1/el unknown
- 2019-06-19 HR HRP20191122TT patent/HRP20191122T1/hr unknown
-
2020
- 2020-05-11 AU AU2020203081A patent/AU2020203081B2/en active Active
-
2021
- 2021-06-30 HR HRP20211035TT patent/HRP20211035T1/hr unknown
- 2021-08-10 CY CY20211100720T patent/CY1124546T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| JP2017528479A5 (hr) | ||
| JP2019031514A5 (hr) | ||
| HRP20200260T1 (hr) | Pripravci, postupci i sustavi za respiratornu isporuku dva ili više aktivnih sredstava | |
| IL256360A (en) | Dry powders of a single metal cation for inhalation | |
| ES2368967T3 (es) | Combinaciones de benzotiazol agonista del adrenorreceptor beta 2. | |
| AU2022201816A8 (en) | Pyrrolopyrimidines as CFTR potentiators | |
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| JP2013536845A5 (hr) | ||
| BR112013019540A2 (pt) | formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas | |
| CA2870158A1 (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| AR070835A1 (es) | Nueva dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios | |
| HRP20211515T1 (hr) | Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni | |
| RU2013103534A (ru) | Лечение легочных инфекций с помощью введения тобрамицина путем аэролизации | |
| JP2015523395A5 (hr) | ||
| HRP20220053T1 (hr) | Farmaceutski sastavi koji sadrže rpl554 u hfa-134a za primjenu inhalacijom | |
| JP2019517541A5 (hr) | ||
| RU2016102630A (ru) | Комплексная гранулированная композиция, обладающая улучшенной стабильностью, включающая левоцетиризин и монтелукаст | |
| HRP20240288T1 (hr) | Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat | |
| HRP20221185T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| JPWO2020074894A5 (hr) | ||
| ES2437690B1 (es) | Formulaciones inhalatorias en forma de soluciones o de polvos secos, para la eliminación de las secreciones mucosas del aparato respiratorio | |
| EA202090172A1 (ru) | Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью | |
| JPWO2021028679A5 (hr) | ||
| JP2019505538A5 (hr) |